1例膜性肾病合并肺部感染患者的药学监护  

Pharmaceutical care on a patient with membranous nephropathy combined with pulmonary infection

作　　者：侯继秋[1] 王冬雪[1] 付秀娟[1] 朱大胜[1] 孙静[1] 柴劲[1] 

机构地区：[1]吉林大学第二医院药品管理部,吉林长春130041

出　　处：《中国药物应用与监测》2015年第4期219-222,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：1例45岁膜性肾病患者,因应用免疫抑制剂出现肺部感染,先后多次调整抗感染药物治疗方案。在应用伏立康唑治疗2 d后患者出现色视、血糖升高不良反应,同时他克莫司血药浓度以及国际标准化比值(INR)升高。在治疗过程中,药师协助医师及时评估免疫抑制方案及抗感染方案,在免疫抑制药物与抗感染药物的调整、药物相互作用的分析、不良反应原因解析等方面进行药学监护。经对症治疗后,患者病情好转出院。One 45-year-old patient with membranous nephropathy got pulmonary infection due to immtmosuppressant, and the anti-infection treatments were adjusted repeatedly. After 2-day treatment of voriconazole, the adverse drug reactions of chromatopsia, hyperglycemia occurred, with the increase of tacrolimus concentration and the INR. During the treatment, pharmacists assisted the physicians in the assessment of immunosuppressive therapy and the anti-infection treatment. And the pharmacists took pharmaceutical cares on adjusting immunosuppressive and anti-infection drugs, analyzing drug interaction and the reasons of ADR. The patient with better condition was discharged after symptomatic treatment.

关 键 词：膜性肾病 肺部感染 药物相互作用 药学监护 

分 类 号：R692[医药卫生—泌尿科学] R563.1[医药卫生—外科学]